Conformational Studies Using Second Derivative UV-Vis Absorption Spectroscopy

Importance of the Topic

The conformational stability of therapeutic monoclonal antibodies is critical for efficacy and safety. As biosimilar products enter the market after patent expirations, analytical methods that can reliably compare their higher order structures with the innovator molecules become essential for quality control and regulatory approval.

Study Objectives and Overview

This study applied second derivative UV-Vis absorption spectroscopy to compare the structural properties of an innovator monoclonal antibody (rituximab) and its biosimilar counterpart. By monitoring spectral shifts of aromatic amino acids, the work aimed to assess whether the two antibodies exhibit similar conformational stability under denaturing conditions.

Methodology

Samples of innovator and biosimilar rituximab were prepared in Tris HCl buffer at pH 6.0 and a concentration of 10 mg/mL. Denaturation was induced by adding guanidine hydrochloride (GdnHCl) at concentrations from 0 to 6 M. High-resolution absorbance spectra were collected from 240 to 350 nm with 0.5 nm intervals. The second derivative of the spectra was calculated using a Savitzky–Golay algorithm, followed by spline interpolation to enhance resolution of the derivative peaks.

Used Instrumentation

• Agilent Cary 60 UV-Vis spectrophotometer with xenon flash lamp optical design
• Cary WinUV software for data processing and derivative calculation
• 3 mL quartz cuvettes with 1 cm path length

Main Results and Discussion

The second derivative spectra resolved contributions from phenylalanine, tyrosine, and tryptophan. Monitoring the negative derivative peak near 291 nm, indicative of tryptophan environment, revealed comparable unfolding profiles for both antibody samples when exposed to increasing GdnHCl concentrations. Analysis of the tyrosine a/b ratio, defined by derivative peak distances, showed similar shifts for innovator and biosimilar, confirming comparable exposure of aromatic residues upon denaturation.

Benefits and Practical Applications of the Method

Second derivative UV-Vis spectroscopy offers a rapid, reagent-free, and non-destructive approach to assess higher order structure of proteins. It can serve as an orthogonal analytical tool in biosimilar comparability studies, complementing techniques such as circular dichroism and chromatography.

Future Trends and Potential Applications

Advances in derivative spectroscopy combined with automated data analysis may enable high-throughput screening of antibody conformational stability. Integration with other biophysical methods and machine learning models could further enhance the detection of subtle structural differences during biosimilar development.

Conclusion

The Agilent Cary 60 UV-Vis spectrophotometer provided the resolution and accuracy needed to compare innovator and biosimilar rituximab structures. Both mAbs displayed similar unfolding behavior in the presence of GdnHCl, supporting their conformational equivalence. Second derivative absorption spectroscopy is thus a valuable technique for biosimilar structural characterization.

References

1. Scott A, Wolchok J, Old L. Antibody therapy of cancer Nat Rev Cancer 2012;12:278–287.
2. Udpa N, Million R. Monoclonal antibody biosimilars Nat Rev Drug Discov 2016;15:13–14.
3. Pace CN, Scholtz JM. Measuring the conformational stability of a protein Protein Struct Pract Approach 1997;299–321.
4. Zheng K, Bantog C, Bayer R. Impact of glycosylation on mAb conformation and stability mAbs 2011;3(6):568–576.
5. Levine R, Federici M. Quantitation of aromatic residues by second-derivative spectroscopy Biochemistry 1982;21:2600–2606.
6. Mach H, Middaugh CR. Monitoring W, Y, and F residues by second-derivative spectroscopy Anal Biochem 1994;222:323–331.
7. Agilent Application Note 5991-4920EN. Comparison of Biosimilar and Innovator Rituximab.
8. Ragone R, Colonna G et al. Determination of tyrosine exposure by second-derivative spectroscopy Biochem 1984;23:1871–1875.
9. Katayama D, Nayar R et al. Solution behavior of interferon-tau J Pharm Sci 2005;94:2703–2715.